Sumanta Kumar Pal, M.D., FASCO | City ...

Dr. Sumanta K. Pal

Claim this profile

City of Hope Medical Center

Studies Kidney Cancer
Studies Renal Cell Carcinoma
15 reported clinical trials
21 drugs studied

Area of expertise

1

Kidney Cancer

Sumanta K. Pal has run 10 trials for Kidney Cancer. Some of their research focus areas include:

Stage IV
RECIST 1.1
metastatic
2

Renal Cell Carcinoma

Sumanta K. Pal has run 9 trials for Renal Cell Carcinoma. Some of their research focus areas include:

Stage IV
RECIST 1.1
metastatic

Affiliated Hospitals

Image of trial facility.

City Of Hope Medical Center

Image of trial facility.

City Of Hope Comprehensive Cancer Center

Clinical Trials Sumanta K. Pal is currently running

Image of trial facility.

Radioactive Drug Therapy

for Prostate Cancer

This trial studies how well lutetium Lu 177 dotatate works in treating patients with a specific type of prostate cancer that has spread. The drug targets cancer cells and releases radiation to kill them. Lutetium-177 (Lu-177) PSMA therapy is a targeted treatment for advanced prostate cancer that has shown promising results.

Recruiting

1 award

Phase 2

16 criteria

Image of trial facility.

Cabozantinib +/− Atezolizumab

for Advanced Kidney Cancer

This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started (primary site) to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the tumor and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of tumor cells. Combination therapy with atezolizumab and cabozantinib may shrink the tumor and allow a longer survival time in patients with metastatic renal cell carcinoma.

Recruiting

1 award

Phase 2

30 criteria

More about Sumanta K. Pal

Clinical Trial Related

8 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Sumanta K. Pal has experience with

  • Nivolumab
  • Cabozantinib S-malate
  • Clostridium Butyricum CBM 588 Probiotic Strain
  • Ipilimumab
  • Pembrolizumab
  • Atezolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Sumanta K. Pal specialize in?

Is Sumanta K. Pal currently recruiting for clinical trials?

Are there any treatments that Sumanta K. Pal has studied deeply?

What is the best way to schedule an appointment with Sumanta K. Pal?

What is the office address of Sumanta K. Pal?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security